Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CENPE | Q02224 | 2/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2105635 | 0.94 | CENPE (0.64) | CENPES1PR1S1PR3S1PR5XDH | |
| SCHEMBL4434702 | 0.89 | CENPE (0.65) | CENPES1PR1S1PR3S1PR5XDH | |
| SCHEMBL13161915 | 0.89 | CENPE (0.65) | CENPES1PR1S1PR3S1PR5XDH | |
| SCHEMBL2104363 | 0.87 | CENPE (0.68) | CENPES1PR1S1PR3S1PR5XDH | |
| SCHEMBL2103780 | 0.87 | CENPE (0.68) | CENPES1PR1S1PR3S1PR5XDH | |
| SCHEMBL4441782 | 0.84 | CENPE (0.68) | CENPES1PR1S1PR3S1PR5XDH | |
| SCHEMBL13161504 | 0.84 | CENPE (0.68) | CENPES1PR1S1PR3S1PR5XDH | |
| SCHEMBL13637408 | 0.84 | CENPE (0.51) | CENPES1PR1 | |
| SCHEMBL2105975 | 0.84 | CENPE (0.63) | CENPES1PR1S1PR3S1PR5XDH | |
| SCHEMBL13161893 | 0.84 | CENPE (0.60) | CENPES1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618981-B2 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20060094708-A1 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INCORPORATED | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094708-A1 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | KIF5B, KIF18A, KIF2C | CENPE 522/4885S1PR1 2246/4885S1PR3 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.